TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 12, 2024
FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
